16th Jul 2009 07:00
|
For Immediate Release |
16th July 2009 |
PLETHORA SOLUTIONS HOLDINGS PLC
PSD503: Development Update
Evaluation and Option Agreement
Plethora Solutions Holdings PLC ("Plethora", AIM: PLE), the specialist developer of products for the treatment and management of urological disorders, announces that it has entered into an evaluation and option agreement for PSD503 with an international pharmaceutical company. Upon completion of the evaluation, Plethora's collaborator has an exclusive option to exclusively license the product for the treatment of stress urinary incontinence (SUI).
SUI is the most common form of urinary incontinence in women and represents a significant market opportunity. It is characterised by urine leakage when pressure is increased in the abdominal cavity; for example during coughing, sneezing, laughing, exercising.
Plethora developed PSD503 to provide an 'on demand' treatment for women suffering from SUI. Epidemiological studies indicate that SUI afflicts half of all female urinary incontinence sufferers (but only 10% of incontinent men), and is the most frequently reported type of incontinence diagnosed in women under 50. The condition can have a significant negative impact on quality of life and self esteem. Plethora has previously reported a successful outcome to a Phase IIa trial in women suffering from stress incontinence.
The evaluation programme will comprise a short clinical study for which Plethora will supply clinical materials and the collaborator will meet the cost of the clinical study.
-Ends-
Enquiries:
|
Plethora Solutions Steven Powell |
Tel : +44(0) 20 3077 5400 |
|
FinnCap Geoff Nash/Marc Young |
Tel : +44(0) 20 7600 1658 |
|
Hansard Group Adam Reynolds/John Bick |
Tel: +44(0) 20 7245 1100 |
About Plethora:
Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503), interstitial cystitis (PSD597), gynaecological pain (PSD508), erectile dysfunction (PSD510) and premature ejaculation (PSD502). The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:PLE)
Further information is available at www.plethorasolutions.co.uk
Related Shares:
Plethora Solutions Holdings Plc